Author:
Selleri Silvia,Deola Sara,Rumio Cristiano,Marincola Francesco M.
Reference124 articles.
1. Matzinger, P. Danger model of immunity. Scand J Immunol, 54: 2–3, 2001.
2. Rehermann, B. and Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol, 5: 215–229, 2005.
3. Wolfel, T., Klehmann, E., Muller, C., Schutt, K. H., Meyer zum Buschenfelde, K. H., and Knuth, A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med, 170: 797–810, 1989.
4. Marincola, F. M., Rivoltini, L., Salgaller, M. L., Player, M., and Rosenberg, S. A. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother, 19: 266–277, 1996.
5. Mantovani, A., Romero, P., Palucka, A. K., and Marincola, F. M. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet, in press, 2006.